Andere talen Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Aandelen

8SJ

CNE100003FF7

Vertraagde tijd Deutsche Boerse AG Andere beurzen 09:59:02 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,4 ^EUR	+1,45%		+2,19%	-46,15%

13/06	Junshi Biosciences' geneesmiddel tegen kanker krijgt registratiecertificaat van Chinese toezichthouder	MT
12/06	Shanghai Junshi Biosciences Co. Ontvangt Registratiecertificaat voor Geneesmiddelen afgegeven door de National Medical Products Administration	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	13/06
Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration	12/06
Junshi Bio Achieves Primary Endpoints in Phase 3 Trial of Liver Cancer Treatment	12/06
Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results	12/06
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint	12/06
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma	11/06
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	25/04
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	25/04
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	24/04
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	24/04
Junshi Biosciences Gets Nod to Register Toripalimab Injection	08/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	07/04
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	03/04
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	02/04
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	02/04
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	29/03
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	29/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Aandelen

8SJ

CNE100003FF7

Andere talen

Filters